Market Eyes LiveEdwards Lifesciences Corp (EW) Stock Rating & Analysis
MELANY's data-driven read on Edwards Lifesciences Corp · Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Edwards Lifesciences, spun off from Baxter International in 2000, designs, manufactures, and markets medical devices and equipment for advanced structural heart disease. It is a leader across key products including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. About 60% of its total sales come from outside the US.
Why EW scores 58/100
MELANY scores Edwards Lifesciences Corp 58/100 by weighing eight factors. Here is how EW breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 26.6x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 78%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for EW
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Edwards Lifesciences Corp sits in the Healthcare sector theme, which MELANY currently rates 26/100 for strength. Theme strength feeds EW's momentum and catalyst factors above.
Tracking EW
Edwards Lifesciences Corp rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add EW to your watchlist and get alerted the moment the rating changes.
How MELANY rates EW
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Edwards Lifesciences Corp's 58/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about EW
Is Edwards Lifesciences Corp (EW) a buy?
As of 2026-08-14, MELANY rated Edwards Lifesciences Corp Hold with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Edwards Lifesciences Corp's MELANY score?
Edwards Lifesciences Corp (EW) has a MELANY composite score of 58/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the EW stock rating calculated?
MELANY scores EW from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Edwards Lifesciences Corp stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Edwards Lifesciences Corp (EW) Hold with a composite of 58/100 as of 2026-08-14. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the EW stock price forecast?
MELANY does not publish price targets or forecasts for EW. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for Edwards Lifesciences Corp, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is EW stock overvalued or undervalued?
MELANY's valuation factor currently reads 38/100 for Edwards Lifesciences Corp, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives EW's read.
What price should I buy EW at?
MELANY is not flagging a fresh entry for EW at its current Hold rating, so there is no entry zone to publish right now. Watchlisting EW in the free app gets you alerted the moment that changes.
What are the risks of buying EW stock?
The top risks MELANY currently flags for Edwards Lifesciences Corp: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Edwards Lifesciences Corp a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 77/100 for Edwards Lifesciences Corp, and earnings track record, at 67/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will EW stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 63/100 for EW right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this EW rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-14. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores EW continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
EW's live rating and alerts are free either way. The app is our flagship.